FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_									_						
1. Name and Address of Reporting Person* <u>Crowley John F</u>						2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [FOLD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
														X	Director		10% Owner		ner	
<i>"</i>	- -									X	Officer below)	(give title		Other (speci						
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023									,	Executive	Cha	below)		
C/O AMICUS THERAPEUTICS, INC.					32	01/01/2020								LACCULTYC Chairman						
3675 MARKET STREET						4 If Amondment Date of Original Filed (Adapth Day A/a-a-)									C. Individual on Initial/Crown Filing (Cheal, Applicable					
(Street)							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
PHILADELPHIA PA 19104															Form filed by One Reporting Person					
					-										Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transaction Date					n 2A. Deemed Execution Date,			3. Transaction		4. Securities Disposed Of			es	Form	: Direct	7. Nature of Indirect Beneficial Ownership				
			(Month/Da	y/Year)	ear) if any (Month/Day/Year)		Code (Instr. 8)					Following (I)		str. 4)						
										v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock			02/01/2	02/01/2023				M		83,333	Α	\$	6.1	1,09	95,389		D			
Common Stock 02/01/2				2023	023					56,596	A	\$5	5.13	1,15	51,985		D			
Common Stock 02/01/202				2023	23		S ⁽¹⁾		147,316	D	\$13.1	1102(2)	1,004,669			D				
Common Stock													64,895			I	By Trust			
		•	Table I								posed of,				wned					
1. Title of	2.	3. Transaction	3A. Dec		puts,	cans	·	ımber			, convertil				8. Price of 9. Number			10.	11. Nature	
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execut if any	ion Date, /Day/Year)	Transa Code (8)		of Derivative Securities Acquired (A) or Disposed		Expiration D (Month/Day/		ate	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		D	Derivative Security Instr. 5)	derivative Securities Beneficially Owned Following Reported	ly	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
					of (D) (Instr. 3, 4 and 5)										Transaction(s) (Instr. 4)					
							П						Amo	ount						
											F		Nun	nber						
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	of Sha	res						
Stock Options (right to buy)	\$6.1	02/01/2023			M			83,333	(3)	06/15/2026	Commo	n 83,	333	\$0.00	0		D		
Stock Options (right to buy)	\$5.13	02/01/2023			M			56,596	(3)	01/03/2027	Commo	n 56,	596	\$0.00	0		D		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022 for estate planning purposes.
- 2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$12.81 to \$13.28 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. All of these options were fully vested and exercisable as of the transaction date.

Remarks:

In addition to the reported transactions which were undertaken for estate planning purposes, Mr. Crowley also has approximately 627,000 options outstanding and exercisable at various strike prices.

/s/ Christian Formica, Attorney- 02/03/2023 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.